Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes

[1] Burger JA(2015)Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia N Engl J Med 373 2425-2437

[2] Tedeschi A(2019)Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia N Engl J Med 381 432-443

[3] Barr PM(2018)Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL N Engl J Med 379 2517-2528

[4] Robak T(2014)Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling Blood. 124 3829-3830

[5] Owen C(2016)Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study Br J Haematol 175 462-466

[6] Ghia P(2014)Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia N Engl J Med 371 213-223

[7] Bairey O(2016)Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study Lancet Oncol 17 200-211

[8] Hillmen P(2016)The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis Blood. 128 138-140

[9] Bartlett NL(2018)Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study Blood. 131 2357-2366

[10] Li J(2017)Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib Blood Adv 1 1739-1748

[1] Burger JA(2015)Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia N Engl J Med 373 2425-2437

[2] Tedeschi A(2019)Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia N Engl J Med 381 432-443

[3] Barr PM(2018)Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL N Engl J Med 379 2517-2528

[4] Robak T(2014)Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling Blood. 124 3829-3830

[5] Owen C(2016)Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study Br J Haematol 175 462-466

[6] Ghia P(2014)Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia N Engl J Med 371 213-223

[7] Bairey O(2016)Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study Lancet Oncol 17 200-211

[8] Hillmen P(2016)The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis Blood. 128 138-140

[9] Bartlett NL(2018)Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study Blood. 131 2357-2366

[10] Li J(2017)Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib Blood Adv 1 1739-1748